JP2008528033A - ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法 - Google Patents

ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法 Download PDF

Info

Publication number
JP2008528033A
JP2008528033A JP2007553266A JP2007553266A JP2008528033A JP 2008528033 A JP2008528033 A JP 2008528033A JP 2007553266 A JP2007553266 A JP 2007553266A JP 2007553266 A JP2007553266 A JP 2007553266A JP 2008528033 A JP2008528033 A JP 2008528033A
Authority
JP
Japan
Prior art keywords
protein
polypeptide
precursor
sequence
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007553266A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008528033A5 (https=
Inventor
ローバート フォーガン ヘイレンベック,
エリザベス ボッシュ,
トーマス リンネマン,
アーネスティン リー,
Original Assignee
ファイブ プライム セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイブ プライム セラピューティクス, インコーポレイテッド filed Critical ファイブ プライム セラピューティクス, インコーポレイテッド
Publication of JP2008528033A publication Critical patent/JP2008528033A/ja
Publication of JP2008528033A5 publication Critical patent/JP2008528033A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2007553266A 2005-01-27 2006-01-27 ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法 Pending JP2008528033A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64701305P 2005-01-27 2005-01-27
PCT/US2006/002951 WO2006081430A2 (en) 2005-01-27 2006-01-27 Leader sequences for directing secretion of polypeptides and methods for production thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009009381A Division JP2009131268A (ja) 2005-01-27 2009-01-19 ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法

Publications (2)

Publication Number Publication Date
JP2008528033A true JP2008528033A (ja) 2008-07-31
JP2008528033A5 JP2008528033A5 (https=) 2009-03-05

Family

ID=36741080

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007553266A Pending JP2008528033A (ja) 2005-01-27 2006-01-27 ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法
JP2009009381A Pending JP2009131268A (ja) 2005-01-27 2009-01-19 ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009009381A Pending JP2009131268A (ja) 2005-01-27 2009-01-19 ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法

Country Status (9)

Country Link
US (1) US20080286834A1 (https=)
EP (1) EP1841874B1 (https=)
JP (2) JP2008528033A (https=)
AT (1) ATE454455T1 (https=)
AU (1) AU2006207999A1 (https=)
CA (1) CA2589895A1 (https=)
DE (1) DE602006011574D1 (https=)
DK (1) DK1841874T3 (https=)
WO (1) WO2006081430A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010183885A (ja) * 2009-02-13 2010-08-26 Kobe Univ タンパク質の製造方法およびそれに用いる発現ベクター

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
US9060961B2 (en) * 2006-11-09 2015-06-23 University Of Washington Molecules and methods for treatment and detection of cancer
WO2009056330A1 (en) * 2007-10-31 2009-05-07 Eth Zurich Soluble truncated apom proteins and medical uses thereof
EP2271358B1 (en) * 2008-03-25 2018-11-21 Amarantus Therapeutics, Inc. use of mesencephalic astrocyte-derived neurotrophic factor for treating Parkinson's disease
FR2933773B1 (fr) * 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
EP2318529B1 (en) 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
WO2010075194A1 (en) * 2008-12-22 2010-07-01 St. Jude Children's Research Hospital Prokaryotic expression of soluble, active dkk
US8445445B2 (en) 2009-09-15 2013-05-21 Five Prime Therapeutics, Inc. Method of promoting hair growth using FGFR4 extracellular domains
LT2498799T (lt) 2009-11-13 2016-11-10 Five Prime Therapeutics, Inc. Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis
EA034462B1 (ru) 2009-11-24 2020-02-11 Алетиа Байотерапьютикс Инк. Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
DK2585098T3 (da) 2010-06-28 2014-11-03 Five Prime Therapeutics Inc Ekstracellulære FZD8-domæner og fusionsmolekyler fraekstracellulære FZD8-domæner til anvendelse ved behandling afobesitet og obesitet-relaterede lidelser
EP2444495A1 (en) * 2010-10-20 2012-04-25 Algenics Secretion of recombinant polypeptides in the extracellular medium of diatoms
KR101910779B1 (ko) 2010-11-15 2018-10-22 파이브 프라임 테라퓨틱스, 인크. Fgfr1 세포밖 도메인 조합치료
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
AU2012205384B2 (en) 2011-01-14 2015-09-10 Five Prime Therapeutics, Inc. IL-27 antagonists for treating inflammatory diseases
CN107823630A (zh) 2011-11-14 2018-03-23 戊瑞治疗有限公司 治疗癌症的方法
US9822170B2 (en) 2012-02-22 2017-11-21 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
RU2670743C9 (ru) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
EP2858679B2 (en) 2012-06-08 2024-06-05 Translate Bio, Inc. Pulmonary delivery of mrna to non-lung target cells
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
EP4331620A3 (en) 2012-12-07 2024-12-04 Translate Bio, Inc. Lipidic nanoparticles for mrna delivery
EP2970940B1 (en) 2013-03-14 2018-07-25 Translate Bio, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
KR102516152B1 (ko) 2013-08-01 2023-03-31 파이브 프라임 테라퓨틱스, 인크. 비푸코실화된 항-fgfr2iiib 항체
SG11201610672YA (en) 2014-06-23 2017-01-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
EP3212670B1 (en) 2014-10-29 2020-12-23 Five Prime Therapeutics, Inc. Combination therapy for cancer
MX2017008218A (es) 2014-12-22 2017-10-18 Five Prime Therapeutics Inc Anticuerpos anti-csf1r para tratar pvns.
RS60614B1 (sr) 2015-03-23 2020-08-31 Jounce Therapeutics Inc Antitela za icos
AU2016249981B2 (en) 2015-04-13 2022-02-17 Five Prime Therapeutics, Inc. Combination therapy for cancer
AU2016342269A1 (en) 2015-10-22 2018-03-29 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
ES2981471T3 (es) 2016-04-25 2024-10-09 Five Prime Therapeutics Inc NOPE para el tratamiento de la pérdida de masa muscular y la debilidad muscular patológicas
HRP20211703T1 (hr) 2016-11-02 2022-02-04 Jounce Therapeutics, Inc. Protutijela protiv pd-1 i njihova upotreba
CN109906030B (zh) 2016-11-04 2022-03-18 安健基因公司 用于产生仅重链抗体的经基因修饰的非人动物和方法
TWI685351B (zh) * 2016-12-29 2020-02-21 財團法人生物技術開發中心 延長蛋白質藥物體內半衰期的激肽原-1衍生胜肽
CN110709420A (zh) 2017-03-31 2020-01-17 戊瑞治疗有限公司 使用抗gitr抗体的癌症组合疗法
US20200024351A1 (en) 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
AU2018281334A1 (en) 2017-06-06 2019-12-19 Kindred Biosciences, Inc. Erythropoietin and analogs for veterinary use
EA202091540A1 (ru) 2017-12-22 2021-03-22 Джаунс Терапьютикс, Инк. Антитела к lilrb2
CN113056483B (zh) 2018-07-09 2025-08-01 戊瑞治疗有限公司 结合到ilt4的抗体
US20220112257A1 (en) * 2019-01-11 2022-04-14 Arbele Limited Mul tispecific prochemokine therapeutic proteins (park) and method of making and using thereof
US20220152098A1 (en) 2019-03-01 2022-05-19 Achelois Biopharma, Inc. Methods of modulating cd160 function in the antigen-specific immune cell and uses thereof
WO2021178001A1 (en) * 2020-03-05 2021-09-10 Curie Co. Inc. Methods for cell free protein expression of mature polypeptides derived from zymogens and proproteins
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
CN116724051A (zh) 2020-08-10 2023-09-08 上海寻百会生物技术有限公司 用于通过靶向igsf8来治疗自身免疫性疾病和癌症的组合物和方法
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039529A1 (en) * 1995-06-06 1996-12-12 Basf Ag Compositions for expression of proteins in host cells using a preprocollagen signal sequence

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1105508T3 (da) * 1998-08-17 2003-01-06 Europ Lab Molekularbiolog Fremgangsmåde til oprensning af biomolekyle- eller proteinkomplekser
US20080242603A1 (en) * 2004-02-20 2008-10-02 Yan Wang Novel Apo2L and IL-24 Polypeptides, Polynucleotides, and Methods of Their Use
EP2479277B1 (en) * 2004-07-22 2015-09-02 Five Prime Therapeutics, Inc. Use of MGD-CSF in a method of treatment of Alzheimer's disease.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039529A1 (en) * 1995-06-06 1996-12-12 Basf Ag Compositions for expression of proteins in host cells using a preprocollagen signal sequence

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010183885A (ja) * 2009-02-13 2010-08-26 Kobe Univ タンパク質の製造方法およびそれに用いる発現ベクター

Also Published As

Publication number Publication date
WO2006081430A2 (en) 2006-08-03
EP1841874A2 (en) 2007-10-10
AU2006207999A1 (en) 2006-08-03
US20080286834A1 (en) 2008-11-20
JP2009131268A (ja) 2009-06-18
EP1841874B1 (en) 2010-01-06
CA2589895A1 (en) 2006-08-03
WO2006081430A9 (en) 2006-11-30
WO2006081430A3 (en) 2007-04-05
DK1841874T3 (da) 2010-05-17
DE602006011574D1 (de) 2010-02-25
ATE454455T1 (de) 2010-01-15

Similar Documents

Publication Publication Date Title
JP2008528033A (ja) ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法
JP4860702B2 (ja) ポリペプチドのリコンビナント発現のための方法
KR101526019B1 (ko) 증대된 단백질 발현 및 정제를 위한 방법 및 조성물
JP6471175B2 (ja) 高効率分泌能を有するタンパク質分泌因子及びこれを含む発現ベクター
CN108610398B (zh) 一段功能序列及在分泌蛋白表达中的应用
JPH0541982A (ja) アミド酵素発現のための宿主および発現ベクタ
AU2016227621B2 (en) System for the presentation of peptides on the cell surface
JP2025081661A (ja) タンパク質発現のためのシステムおよび方法
JPWO2018074498A1 (ja) リムルス属由来の組換え蛋白質及びこれをコードするdna
TW201815818A (zh) 細胞相關之分泌增強融合蛋白
CN112592388A (zh) 一种2a肽、双顺反子表达载体、重组蛋白表达系统及应用
CN109666699B (zh) 一种基于lag-3/mhc ii阻断功能及其生物效应的药物快速筛选方法
JP4604184B2 (ja) 新規糖鎖認識蛋白質及びその遺伝子
JP2009502117A (ja) 赤血球新生刺激タンパク質生成のための組み換え法
CN109790214B (zh) 用于选择产生多肽的细胞的改进方法
JP2004520056A (ja) 可溶性ssaoの精製のための方法
WO2020139855A2 (en) Chimeric signal peptides for protein production
CN103717743A (zh) pAVEC
WO2022192597A2 (en) Affinity agents
EP1352060A2 (en) Methods for expressing endogenous genes by restriction enzyme mediated integration
Skelly et al. Classical cloning, expression, and purification
HK40008758B (en) Improved method for selecting polypeptide producing cells
HK40008758A (en) Improved method for selecting polypeptide producing cells
BR122024010970A2 (pt) Fator de secreção de proteína, cassete de expressão, vetor para a expressão secretória de proteína alvo, célula transformada compreendendo o dito vetor e método para produzir uma proteína alvo
AU2002232349A1 (en) Method for purification of soluble SSAO

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111003

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111011

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120306